Business Description
NextCure Inc
NAICS : 325412
SIC : 2834
ISIN : US65343E1082
Total Employee Number:
40Description
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.67 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14.4 | |||||
3-Year EPS without NRI Growth Rate | 15.2 | |||||
3-Year FCF Growth Rate | 10.3 | |||||
3-Year Book Growth Rate | -48.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 42.32 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.61 | |||||
Quick Ratio | 4.61 | |||||
Cash Ratio | 4.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.8 | |||||
Shareholder Yield % | -10.43 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -158.17 | |||||
ROA % | -112.66 | |||||
ROIC % | -764.31 | |||||
3-Year ROIIC % | -138.32 | |||||
ROC (Joel Greenblatt) % | -856.92 | |||||
ROCE % | -141.93 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.73 | |||||
Price-to-Tangible-Book | 0.73 | |||||
EV-to-EBIT | 0.07 | |||||
EV-to-Forward-EBIT | -1.66 | |||||
EV-to-EBITDA | 0.07 | |||||
EV-to-FCF | 0.08 | |||||
| Price-to-Net-Current-Asset-Value | 0.96 | |||||
| Price-to-Net-Cash | 1.06 | |||||
Earnings Yield (Greenblatt) % | 1428.57 | |||||
FCF Yield % | -226.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NextCure Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -14.838 | ||
| Beta | 0.8997 | ||
| 3-Year Sharpe Ratio | -0.7 | ||
| 3-Year Sortino Ratio | -0.89 | ||
| Volatility % | 3.41 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 4.728 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 4.728 - 4.728 | ||
| Shares Outstanding (Mil) | 4.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NextCure Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NextCure Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 99 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 9 days | ||
| General meeting for 2026 | 2026-06-18 11:00 | 4.73 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-02 08:00 | 4.73 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 4.73 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 16:05 | 4.73 (+0.00%) | ||
| Annual report for 2025 | 2026-03-05 | 4.73 (+0.00%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-03 11:00 | 4.73 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 4.73 (+0.00%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 16:00 | 4.73 (+0.00%) |
Show
Entries
NextCure Inc Frequently Asked Questions
What is NextCure Inc(FRA:2US0)'s stock price today?
The current price of FRA:2US0 is €4.73. The 52 week high of FRA:2US0 is €4.73 and 52 week low is €4.73.
When is next earnings date of NextCure Inc(FRA:2US0)?
The next earnings date of NextCure Inc(FRA:2US0) is 2026-08-07 Est..
Does NextCure Inc(FRA:2US0) pay dividends? If so, how much?
NextCure Inc(FRA:2US0) does not pay dividend.
Press Release
Articles on NextCure Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers